Back to Authors

Pagan-Rosado, Robert

Mayo Clinic

Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota.

Citations 2

CellKine clinical trial: first report from a phase 1 trial of allogeneic bone marrow–derived mesenchymal stem cells in subjects with painful lumbar facet joint arthropathy
Yan, Dan , Osborne, Michael D. , Durand, Nisha , Kubrova, Eva , Witter, Drew M., Baer, Meghan M., Ponce, Gabriela C., Quiñones‐Hinojosa, Alfredo , Qu, Wenchun , Engelberg-Cook, Erica , Pagan-Rosado, Robert, Stone, Jeffrey A, Lehman, Vance T. , Durand, Nisha C, Zubair, Abba C. , Pagan‐Rosado, Robert , Stone, Jeffrey A., Wang, Zhen

PAIN Reports | September 19, 2024 | Volume: 9 | Issue: 5 | Pages: e1181

10.1097/pr9.0000000000001181 Get It

Abstract Background: Lumbar facet joint arthropathy (LFJA) is a major cause of low back pain (LBP), with current treatments offering limited long-term benefits. Bone marrow–derived mesenchymal stem cells (BM-MSCs) show promise due to their immunomodulatory and trophic effects, potentially addressing underlying degenerative processes in LFJA. Objectives: This initial report describes the outcomes of the first treated patient in an ongoing mutidisciplinary phase 1 clinical trial evaluating the safety and feasibility of intra-articular allogeneic BM-MSCs for painful LFJA. Methods: Following enrollment in our IRB-approved protocol, symptomatic LFJA was confirmed through double blocks on L4 and L5 medial branches. Two 1-mL syringes, each containing 10 million BM-MSCs, were prepared in the cGMP facility and administered bilaterally to the patient’s L4-L5 lumbar facet joints. The patient underwent standardized follow-ups, including clinical examinations and functional and imaging assessments for 2 years, utilizing patient-reported outcomes measurement information system—computer adaptive tests (PROMIS CATs), visual analogue scale, Oswestry disability index, work functional status and opioid pain medication use, and MR imaging Fenton–Czervionke score. Results: The patient tolerated the procedure well, with no drug-related adverse events during the study period. Pain, spine function, and work functional status improved at multiple follow-ups. This patient also reported improvements in mental and social health, along with a notable improvement in the grade of facet synovitis observed at the one-year follow-up MRI evaluation. Conclusions: This case report suggests the safety and feasibility of administering intra-articular allogeneic BM-MSCs, offering therapeutic benefits for pain management and functional activities.
Peripheral Nerve Stimulation for Chronic Intractable Neuropathic Pain Following a Brachial Plexus Avulsion Injury: A Case Report
Tate, Quinn , Hurdle, Mark Friedrich B., Pagan-Rosado, Robert, Hallo-Carrasco, Alejandro, Pagan‐Rosado, Robert , Hallo‐Carrasco, Alejandro

A&A Practice | May 5, 2023 | Volume: 17 | Issue: 5 | Pages: e01681

10.1213/xaa.0000000000001681 Get It

Brachial plexus avulsion injuries result in permanent motor and sensory deficits, leading to debilitating symptoms. We report the case of a 25-year-old man with chronic pain following right-sided C5-T1 nerve root avulsion without evidence of peripheral nerve injury. His pain was recalcitrant to medical and neurosurgical interventions. However, he experienced substantial (>70%) pain relief with peripheral nerve stimulation targeting the median nerve. These results agree with data suggesting collateral sprouting of sensory nerves occurs following a brachial plexus injury. Further study is needed if we are to understand the mechanisms of the peripheral nerve stimulator as a treatment option.